tradmap

XFOR X4 Pharmaceuticals, Inc

$4.05 +0.12%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

X4 Pharmaceuticals, Inc (XFOR) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $402 million. Shares last traded at $4.05, 16.1% below their 52-week high. Over the past year the stock is up 28.0%. Net profit margin is -256.7%, below the peer median of 5.3%. Revenue grew 1273.2% year over year.

Market Cap
$402M
Shares Out
99.1M
EPS (TTM)
$-6.91
P/E Ratio
P/S Ratio
11.44
P/B Ratio
2.58
Dividend / Share
Dividend Yield
52-Week High
$4.83
52-Week Low
$2.80
Volume
42,338
Avg Vol (3m)
54,845.302

Performance

1W
-4.03%
1M
-2.29%
3M
+1.25%
6M
+9.46%
YTD
+4.38%
1Y
+27.96%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
47.10
SMA (50)
$4.08
SMA (200)
$3.94
Price vs SMA50
-0.74%
Price vs SMA200
+2.85%
ATR (14)
$0.24

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$35M
Net Income
$-90M
Gross Margin
36.8%
Operating Margin
-250.3%
Net Margin
-256.7%
Return on Equity
-58.0%
Return on Assets
-35.6%
Current Ratio
11.30
Debt / Equity
0.48
Revenue Growth (YoY)
+1273.2%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.29 2026-08-06
Q1 2026 $-0.16 2026-05-06
FY 2025 $-1.87 2026-03-17
Q3 2025 $-2.87 2025-11-05
Q2 2026 $-3.59 2026-08-06
Q1 2026 $0.04 2026-05-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

XFOR vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
11.44 / 19.49 med
-41% discount
Net margin vs peers
-256.7% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.